Highlights Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Market Closed - Nyse Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
0.165 ^USD	-1.61%		-4.40%	-23.68%

May. 09	Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	Apr. 30	CI
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	Mar. 25	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	CI
Matinas Reaches Agreement With FDA For Late-Stage Invasive Aspergillosis Trial	Feb. 20	MT
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis	Feb. 20	CI
Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides	Dec. 27	CI
Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA	Dec. 21	CI
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model	Nov. 07	CI
Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient?s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203	23-10-11	CI
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases	23-08-22	CI
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Matinas BioPharma Holdings, Inc. Announces That Matinas Biopharma Holdings Inc.'S Oral Presentation At the 33 European Congress of Clinical Microbiology & Infectious Diseases	23-04-18	CI
Matinas BioPharma Holdings, Inc. Announces Collaboration with National Resilience, Inc. to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids	23-01-12	CI
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%	22-10-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Highlights

Filters